CME/CE Information

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

• Review the recommended algorithm for definitive diagnosis of limb-girdle muscle weakness
• Discuss available testing options (including genetic and non-genetic components), including optimal use and timing and effective interpretation
• Describe important facets of a management plan for various types of limb-girdle muscle disorder, including pharmacologic therapies, multiple specialty involvement, and clinical trials consideration

ACTIVITY FACULTY

Anthony A. Amato, MD
Neurologist
Brigham and Women’s Hospital
Professor of Neurology
Harvard Medical School
Boston, Massachusetts

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity.
4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice, the perception of commercial bias, and whether or not the objectives were met.
6. Your CME/CE certificate will be available for download

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association.

TARGET AUDIENCE

This activity is intended for neurologists, physical medicine and rehabilitation (PMR) physicians, neuromuscular specialists, genetic counselors and other healthcare professionals who manage patients with muscle and nerve disorders.

STATEMENT OF NEED

Limb girdle muscle weakness (LGMW) can result from multiple causes. Early and accurate diagnosis is critical to optimal disease management. The diagnosis can involve clinical, electromyogram, and genetic findings. Patient-specific multidisciplinary management plans, including genetic counseling, should be developed. Currently, there are drugs available for some conditions. Many providers lack the skills to provide optimal care due to the heterogeneous presentation, complex diagnosis, and rarity of LGMW disorders.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Society of Genetic Counselors (NSGC) has authorized the France Foundation to offer up to 0.05 CEUs or 0.50 Category 1 contact hours for the activity: Approach to Genetic Testing in Myopathies. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the National Society of Genetic Counselors who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the Muscular Dystrophy Association who control content have no relevant financial relationships to disclose.

Faculty Disclosures

Anthony A. Amato, MD has received a research grant from the NIH and has served on the advisory board/consultant for Acceleron, Akashi, Biogen, Idera, and Regeneron.

DISCLOSURE OF UNLABELED USE

The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Genzyme, a Sanofi company.

DISCLAIMER

The France Foundation, The National Society of Genetic Counselors, and the Muscular Dystrophy Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the National Society of Genetic Counselors, and the Muscular Dystrophy Association assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2015 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.